PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS
    6.
    发明公开
    PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS 审中-公开
    药物活性化合物AS DAG脂肪酶

    公开(公告)号:EP3145935A1

    公开(公告)日:2017-03-29

    申请号:EP16727341.6

    申请日:2016-05-23

    CPC分类号: C07D498/04 C07D263/56

    摘要: The present invention relates to novel compounds which are selective inhibitors of diacylglycerol lipase alpha and beta. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by increased 2-arachidonoylglycerol levels. Diacylglycerol lipase-a (alternative name: Snl-specific diacylglycerol hydrolase a; DAGL-a) and -β are enzymes responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. Selective and reversible inhibitors are required to study the function of DAGLs in neuronal cells in an acute and temporal fashion. The inventive compounds are in particular suitable for the treatment of neurodegenerative diseases, inflammatory diseases, drug abuse and impaired energy balance, such as obesity, wherein X
    1 is -CH-, -CF- or -N-.